Rising Demand for Biologics, Cost Efficiency, and Regulatory Support Drive Growth in the North America Pharmaceutical Contract Manufacturing Market

North America pharmaceutical contract manufacturing was valued at $96.5 billion in 2024 and is projected to reach $270.0 billion by 2035, growing at a CAGR of 9.9% during the forecast period (2025–2035). The North America pharmaceutical contract manufacturing market is witnessing strong growth driven by rising demand for biologics, complex therapies, and specialty drugs. Outsourcing production helps pharmaceutical companies achieve operational flexibility, reduce capital expenditure, and accelerate time-to-market for new therapies.

Browse the full report description of “North America Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Category (Human-Based Drugs, and Animals Based Drugs), By Type (Sterile Manufacturing, and Non-Sterile Manufacturing), By Product (Over-The-Counter (OTC) Drugs, Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, and Others) and By Services (Manufacturing Services, Non-Clinical Services, and Research and Development), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/north-american-pharmaceutical-contract-manufacturing-market

At the same time, supportive regulatory frameworks and domestic manufacturing initiatives in the U.S. and Canada are encouraging local production and compliance. These factors, combined with increasing focus on cost efficiency and scalable manufacturing solutions, are fueling the adoption of contract manufacturing services across the region.

Real-Life Developments Highlight the Growth of Pharmaceutical Contract Manufacturing in North America

• 2025: Industry data from the Pharmaceutical Research and Manufacturers of America (PhRMA) highlighted that outsourcing to CMOs enabled faster scale-up of specialty drugs and reduced capital investment for domestic manufacturers.
• 2024: The U.S. Food and Drug Administration (FDA) reported a significant increase in biologics and complex therapy approvals, prompting pharmaceutical companies to outsource production to contract manufacturing organizations (CMOs) to meet demand efficiently.
• 2024-2025: Government initiatives, including incentives for domestic manufacturing and regulatory support for high-quality production, encouraged pharmaceutical companies to partner with CMOs, enhancing local production capacity and operational flexibility.

Strategic Industry Initiatives and Manufacturing Innovations

Pharmaceutical contract manufacturing organizations (CMOs) in North America are expanding capabilities for biologics, advanced therapies, and high-potency drugs to meet growing client demand. Companies are investing in flexible, modular facilities, automation, and quality-compliant processes to enhance efficiency and scalability.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Category
• Type
• Product
• Services

• Competitive Landscape – Baxter Biopharma Solutions (Baxter International Inc.), Catalent Inc., Charles River Laboratories, Pfizer CentreOne (Pfizer Inc.) and Thermo Fisher Scientific Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

North America Pharmaceutical Contract Manufacturing Market Report Segment

By Category

• Human-Based Drugs
• Animal-Based Drug

By Type

• Sterile Manufacturing
• Non-Sterile Manufacturing

By Product

• Over-The-Counter (OTC) Drugs
• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulation
• Others (nutritional products and packaging)

By Services

• Manufacturing Services
• Non-Clinical Services
• Research and Development

North America Pharmaceutical Contract Manufacturing Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-pharmaceutical-contract-manufacturing-market